179 related articles for article (PubMed ID: 17564702)
1. Combined immunization with adjuvant molecules poly(I:C) and anti-CD40 plus a tumor antigen has potent prophylactic and therapeutic antitumor effects.
Llopiz D; Dotor J; Zabaleta A; Lasarte JJ; Prieto J; Borrás-Cuesta F; Sarobe P
Cancer Immunol Immunother; 2008 Jan; 57(1):19-29. PubMed ID: 17564702
[TBL] [Abstract][Full Text] [Related]
2. Peptide inhibitors of transforming growth factor-beta enhance the efficacy of antitumor immunotherapy.
Llopiz D; Dotor J; Casares N; Bezunartea J; Díaz-Valdés N; Ruiz M; Aranda F; Berraondo P; Prieto J; Lasarte JJ; Borrás-Cuesta F; Sarobe P
Int J Cancer; 2009 Dec; 125(11):2614-23. PubMed ID: 19530254
[TBL] [Abstract][Full Text] [Related]
3. Immunization against a dominant tumor antigen abrogates immunogenicity of the tumor.
Makki A; Weidt G; Blachere NE; Lefrançois L; Srivastava PK
Cancer Immun; 2002 Apr; 2():4. PubMed ID: 12747749
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors.
Aranda F; Llopiz D; Díaz-Valdés N; Riezu-Boj JI; Bezunartea J; Ruiz M; Martínez M; Durantez M; Mansilla C; Prieto J; Lasarte JJ; Borrás-Cuesta F; Sarobe P
Cancer Res; 2011 May; 71(9):3214-24. PubMed ID: 21402711
[TBL] [Abstract][Full Text] [Related]
5. CD40-activated B cells induce anti-tumor immunity in vivo.
Wennhold K; Weber TM; Klein-Gonzalez N; Thelen M; Garcia-Marquez M; Chakupurakal G; Fiedler A; Schlösser HA; Fischer R; Theurich S; Shimabukuro-Vornhagen A; von Bergwelt-Baildon M
Oncotarget; 2017 Apr; 8(17):27740-27753. PubMed ID: 26934557
[TBL] [Abstract][Full Text] [Related]
6. Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40.
Zabaleta A; Arribillaga L; Llopiz D; Dotor J; Lasarte JJ; Prieto J; Borrás-Cuesta F; Esteban JI; Quer J; Vayreda F; Sarobe P
Antiviral Res; 2007 Apr; 74(1):25-35. PubMed ID: 17275104
[TBL] [Abstract][Full Text] [Related]
7. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of dendritic cells.
Sun JB; Eriksson K; Li BL; Lindblad M; Azem J; Holmgren J
Clin Immunol; 2004 Jul; 112(1):35-44. PubMed ID: 15207780
[TBL] [Abstract][Full Text] [Related]
9. Combined adjuvants of poly(I:C) plus LAG-3-Ig improve antitumor effects of tumor-specific T cells, preventing their exhaustion.
Kano Y; Iguchi T; Matsui H; Adachi K; Sakoda Y; Miyakawa T; Doi S; Hazama S; Nagano H; Ueyama Y; Tamada K
Cancer Sci; 2016 Apr; 107(4):398-406. PubMed ID: 27079438
[TBL] [Abstract][Full Text] [Related]
10. The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo.
Deronic A; Nilsson A; Thagesson M; Werchau D; Enell Smith K; Ellmark P
Cancer Immunol Immunother; 2021 Dec; 70(12):3629-3642. PubMed ID: 33948686
[TBL] [Abstract][Full Text] [Related]
11. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
12. Transcutaneous immunization with imiquimod is amplified by CD40 ligation and results in sustained cytotoxic T-lymphocyte activation and tumor protection.
Warger T; Rechtsteiner G; Schmid B; Osterloh P; Schild H; Radsak MP
Clin Rev Allergy Immunol; 2007 Feb; 32(1):57-66. PubMed ID: 17426361
[TBL] [Abstract][Full Text] [Related]
13. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells.
Okada N; Saito T; Masunaga Y; Tsukada Y; Nakagawa S; Mizuguchi H; Mori K; Okada Y; Fujita T; Hayakawa T; Mayumi T; Yamamoto A
Cancer Res; 2001 Nov; 61(21):7913-9. PubMed ID: 11691812
[TBL] [Abstract][Full Text] [Related]
14. Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs.
Zhang Y; Wakita D; Chamoto K; Narita Y; Matsubara N; Kitamura H; Nishimura T
Int Immunol; 2007 Feb; 19(2):151-61. PubMed ID: 17189593
[TBL] [Abstract][Full Text] [Related]
15. Synergy effects of Polyinosinic-polycytidylic acid, CpG oligodeoxynucleotide, and cationic peptides to adjuvant HPV E7 epitope vaccine through preventive and therapeutic immunization in a TC-1 grafted mouse model.
Liu C; Chu X; Sun P; Feng X; Huang W; Liu H; Ma Y
Hum Vaccin Immunother; 2018 Apr; 14(4):931-940. PubMed ID: 29271696
[TBL] [Abstract][Full Text] [Related]
16. A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy.
Narayanan P; Lapteva N; Seethammagari M; Levitt JM; Slawin KM; Spencer DM
J Clin Invest; 2011 Apr; 121(4):1524-34. PubMed ID: 21383499
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines.
Ceglia V; Zurawski S; Montes M; Kroll M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
Front Immunol; 2021; 12():786144. PubMed ID: 35095862
[TBL] [Abstract][Full Text] [Related]
18. CD40 and CD70 co-stimulate a potent in vivo antitumor T cell response.
Nieland JD; Graus YF; Dortmans YE; Kremers BL; Kruisbeek AM
J Immunother; 1998 May; 21(3):225-36. PubMed ID: 9610915
[TBL] [Abstract][Full Text] [Related]
19. Toll-like receptor 3-induced immune response by poly(d,l-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy.
Han HD; Byeon Y; Kang TH; Jung ID; Lee JW; Shin BC; Lee YJ; Sood AK; Park YM
Int J Nanomedicine; 2016; 11():5729-5742. PubMed ID: 27843314
[TBL] [Abstract][Full Text] [Related]
20. Immunization with antigenic peptides complexed with β-glucan induces potent cytotoxic T-lymphocyte activity in combination with CpG-ODNs.
Mochizuki S; Morishita H; Kobiyama K; Aoshi T; Ishii KJ; Sakurai K
J Control Release; 2015 Dec; 220(Pt A):495-502. PubMed ID: 26562685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
